| Autor: |
Wolner, Z.J., Flowers, N.I., Yushak, M.L., Chen, S.C., Yeung, H. |
| Předmět: |
|
| Zdroj: |
British Journal of Dermatology; Jul2021, Vol. 185 Issue 1, p221-223, 3p |
| Abstrakt: |
Dear Editor, Cutaneous melanomas are the fifth most common cancer in the USA and the UK, with a 5-year relative survival rate of 87-93%.1,2 Targeted and immune checkpoint therapies have further expanded the number of survivors of advanced melanoma. Eligible patients had a histologically confirmed diagnosis of cutaneous melanoma and completed either surgical treatment with no plans of initiating systemic treatment, or at least 12 months of systemic treatment with no evidence of residual disease or stable disease. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text